UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 530

Sortiert nach

Regulatory B cells in anti-tumor immunity

International immunology, 2015-10, Vol.27 (10), p.521-530

2015

Link zum Volltext

Verfügbarkeit prüfen

B cell regulation of the anti-tumor response and role in carcinogenesis

Journal for Immunotherapy of Cancer, 2016-07, Vol.4 (1), p.40-40, Article 40

2016

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2190-2196

2012

Link zum Volltext

Verfügbarkeit prüfen

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2183-2189

2012

Link zum Volltext

Verfügbarkeit prüfen

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Blood, 2016-09, Vol.128 (12), p.1562-1566

2016

Link zum Volltext

Verfügbarkeit prüfen

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Blood, 2015-02, Vol.125 (8), p.1236-1243

2015

Link zum Volltext

Verfügbarkeit prüfen

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Blood, 2017-12, Vol.130 (25), p.2709-2717

2017

Link zum Volltext

Verfügbarkeit prüfen

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

The lancet oncology, 2022-01, Vol.23 (1), p.91-103

2022

Link zum Volltext

Verfügbarkeit prüfen

Advances in Tumor Immunology and Immunotherapy

2014, 2013

Link zum Volltext

Verfügbarkeit prüfen

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

British journal of haematology, 2009-07, Vol.146 (2), p.171-179

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2009-09, Vol.27 (26), p.4371-4377

2009

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Clinical cancer research, 2012, Vol.18 (1), p.248-255

2012

Link zum Volltext

Verfügbarkeit prüfen

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution

Journal of clinical oncology, 2018-12, Vol.36 (34), p.JCO1800138-3380

2018

Link zum Volltext

Verfügbarkeit prüfen

The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model

Cancer Immunology, Immunotherapy, 2011-05, Vol.60 (5), p.609-619

2011

Link zum Volltext

Verfügbarkeit prüfen

B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion

Cancer Immunology, Immunotherapy, 2013-01, Vol.62 (1), p.87-99

2013

Link zum Volltext

Verfügbarkeit prüfen

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Journal of hematology and oncology, 2014-03, Vol.7 (1), p.24-24, Article 24

2014

Link zum Volltext

Verfügbarkeit prüfen

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity

Blood, 2017-04, Vol.129 (16), p.2246-2256

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma

Leukemia & lymphoma, 2020-12, Vol.61 (13), p.3234-3238

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of frontline 90 Y-ibritumomab tiuxetan in marginal zone lymphoma

Leukemia & lymphoma, 2020-12, Vol.61 (13), p.3234-3238

2020

Link zum Volltext

Verfügbarkeit prüfen

CD30: an important new target in hematologic malignancies

Leukemia & lymphoma, 2011-09, Vol.52 (9), p.1641-1654

2011

Link zum Volltext

Verfügbarkeit prüfen

Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti‐tumor CTL and TH1 cytokine responses by B cells

International journal of cancer, 2005-11, Vol.117 (4), p.574-586

2005

Link zum Volltext

Verfügbarkeit prüfen

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

American journal of hematology, 2019-05, Vol.94 (5), p.585-596

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

Blood, 2008-02, Vol.111 (4), p.1848-1854

2008

Link zum Volltext

Verfügbarkeit prüfen

R‐MACLO‐IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma ‐ Long term follow up results

American journal of hematology, 2021-06, Vol.96 (6), p.680-689

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 530

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(441)
Mit Volltextzugriff
(462)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Regulatory B cells in anti-tumor immunity

B cell regulation of the anti-tumor response and role in carcinogenesis

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Advances in Tumor Immunology and Immunotherapy

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution

The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity

Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma

Long-term outcomes of frontline 90 Y-ibritumomab tiuxetan in marginal zone lymphoma

CD30: an important new target in hematologic malignancies

Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti‐tumor CTL and TH1 cytokine responses by B cells

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

R‐MACLO‐IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma ‐ Long term follow up results

Suchergebnisse filtern